Transplantation Proceedings

Foreword
pp. 3939-3939(1)
Authors: Chatenoud L.; Hammer C.; Yussim A.

Development of severe adverse effects after discontinuing amiodarone therapy in human heart transplant recipients
pp. 3943-3944(2)
Authors: Preuner J.G.; Lehle K.; Keyser A.; Merk J.; Rupprecht L.; Goebels R.

Effectiveness of immunosuppressive treatment for recurrent or refractory pancreas allograft rejection: correlation with histologic grade
pp. 3945-3945(1)
Authors: Papadimitriou J.C.; Wiland A.; Drachenberg C.B.; Klassen D.K.; Bartlett S.T.

Hepatitis B and C virus-induced diseases and acute rejection after liver transplantation
pp. 3946-3947(2)
Authors: Maggi U.; Rossi G.; Vannelli A.; Caccamo L.; Gatti S.; Paone G.; Reggiani P.; Melada E.; Latham L.; Andreani P.; Fassati L.R.

Cyclosporin impairs bile duct arterial supply in ischemic livers
pp. 3948-3948(1)
Authors: Nakache R.; Almogy N.; Fiodorov D.; Weinbroum A.

Presence of igg exhibiting a morphine-like activity in therapeutic intravenous immunoglobulins
pp. 3949-3949(1)
Authors: Mace G.; Blanpied C.; Emorine L.J.; Druet P.; Dietrich G.

Hypertriglyceridemia in renal transplant recipients treated with sirolimus
pp. 3950-3951(2)
Authors: Brattstrom C.; Wilczek H.E.; Tyden G.; Bottiger Y.; Sawe J.; Groth C.G.

Monthly cyclophosphamide pulses in the treatment of crescentic glomerulonephritis
pp. 3952-3954(3)
Authors: De La Torre M.; Alcazar R.; Urra J.M.; Caparros G.; Alegre R.; Blanco J.; Nieto J.; Ferreras I.

Conversion of stable renal transplant recipients from sandimmune to sang-35, a neoral-equivalent cyclosporine formulation, using a dose-adjusted method
pp. 3955-3957(3)
Authors: First M.R.; Weiskittel P.; Shah M.; Peddi V.R.; Canafax D.; Schroeder T.J.

Concomitant detection by flow cytometry of the intragranular antigen granzyme B and the intranuclear antigen Ki-67 in peripheral blood mononuclear cells from healthy individuals and patients with acute CMV infection after renal transplantation
pp. 3958-3959(2)
Authors: Rentenaar R.J.; Wever P.C.; van Diepen F.N.J.; Out T.A.; Schellekens P.T.A.; ten Berge I.J.M.

Irradiation or temporal variations in immunosuppressive schedules do not prevent graft-versus-host disease following rat limb allotransplantation
pp. 3960-3961(2)
Authors: Lui L.T.; Lai Y.C.; Yeh L.S.; Hou S.M.; Jeng C.R.; Gregory C.R.

Outcome of liver transplantation after acute rejection and sepsis
pp. 3962-3966(5)
Authors: Avolio A.W.; Agnes S.; Chirico A.S.A.; Citterio F.; Montemagno S.; Castagneto M.

Humoral and cell-mediated factors involved in the suppressive regulation induced by special blood derivatives and their clinical relevance
pp. 3967-3971(5)
Authors: Padanyi A.; Horuzsko A.; Gyodi E.; Reti M.; Pocsik E.; Kotlan B.; Perner F.; Petranyi G.

Increased systemic levels of soluble granzymes A and B during primary cytomegalovirus infection after renal transplantation
pp. 3972-3974(3)
Authors: ten Berge I.J.M.; Wever P.C.; Wolbink A.M.; Surachno J.; Wertheim P.M.E.; Spaeny L.H.A.; Hack C.E.

Selective expansion of a peripheral blood CD8⁺ memory T cell subset expressing both granzyme B and l-selectin during primary viral infection in renal allograft recipients
pp. 3975-3977(3)
Authors: ten Berge I.J.M.; Wever P.C.; Rentenaar R.J.; Spaeny L.H.A.; Surachno J.; Wertheim P.M.E.; Schellekens P.T.A.; Hack C.E.

Docosahexaenoic and eicosapentaenoic acids inhibit the CD28-lymphocyte activation pathway in vitro
pp. 3978-3979(2)
Authors: Khalfoun B.; Sibue D.; Bardos P.; Lebranchu Y.

Malononitrilamides prevent and suppress allospecific antibody production
pp. 3980-3980(1)
Authors: Qi Z.; Ekberg H.

Possible role of post renal transplant graft-versus-host antibodies in preventing acute graft rejection
pp. 3981-3983(3)
Authors: Jakab J.; Borka P.; Hoffer I.; Perner F.; Gyodi E.; Rajczy K.; Petranyi G.; Szabo J.

Allospecific t-cell receptor v-beta repertoire in human mixed lymphocyte cultures is conserved and oligoclonally restricted
pp. 3984-3985(2)
Authors: Mancia L.; Camponeschi B.; Parisi F.; Vinciguerra G.; Rossi P.

Chronic allograft vasculopathy: new strategies for drug development
pp. 3989-3990(2)
Author: Hayry P.

Cytokine genotypes in allograft rejection: guidelines for immunosuppression
pp. 3991-3992(2)
Authors: Hutchinson I.V.; Turner D.; Sankaran D.; Awad M.; Pravica V.; Sinnott P.

Chronic rejection: an update on the mechanism
pp. 3993-3995(3)
Author: Hayry P.

Cytotoxic T lymphocytes and cytokines in graft vascular disease after clinical heart transplantation
pp. 3996-3998(3)
Authors: Weimar W.; van Besouw N.M.; Baan C.C.; Balk A.H.M.M.

Indirect allorecognition of donor HLA-DR peptides in chronic rejection of heart allografts
pp. 3999-4000(2)
Authors: Suciu-Foca N.; Ciubotariu R.; Itescu S.; Rose E.A.; Cortesini R.

Adverse effects of immunosuppressive drugs on long-term graft outcome - Long-Term Results
pp. 4001-4004(4)
Author: Paul L.C.

Tolerance induction by megadose stem cell transplants: synergism between SCA-1⁺Lin^- cells and nonalloreactive T cells
pp. 4007-4008(2)
Authors: Bachar-Lustig E.; Li H.W.; Marcus H.; Reisner Y.

Specific immunosuppression of the indirect recognition pathway
pp. 4009-4010(2)
Authors: Suciu-Foca N.; Cortesini R.

Short and long-term results after pretransplant high-dose single ATG-fresenius bolus in cadaveric kidney transplantation
pp. 4011-4014(4)
Authors: Kaden J.; Strobelt V.; May G.

In vitro functional properties of antithymocyte globulins: clues for new therapeutic applications? - Principle and Practice
pp. 4015-4017(3)
Authors: Bonnefoy-Berard N.; Fournel S.; Genestier L.; Flacher M.; Quemeneur L.; Revillard J.P.

Dissociation between chimerism and skin graft tolerance after neonatal injection of allogenic spleen cells
pp. 4018-4019(2)
Authors: Donckier V.; Flamand V.; Abramowicz D.; Goldman M.

Hematopoietic chimerism and tolerance of T cells, B cells, and NK cells
pp. 4020-4020(1)
Authors: Sykes M.; Ohdan H.; Manilay J.O.; Wekerle T.; Yang Y.-G.

Deletion of donor-reactive cells followed by stem cell transplantation in recipients treated with total lymphoid-irradiation as a means for induction of transplantation tolerance to organ allografts and xenografts
pp. 4021-4022(2)
Authors: Slavin S.; Gurevitch O.; Zhu J.; Prighozina T.

A new large-animal model for research of graft vascular disease
pp. 4023-4023(1)
Authors: Gummert J.F.; Ikonen T.; Briffa N.; Honda Y.; Hayase M.; Perlroth J.; Kobayashi Y.; Hausen B.; Barlow C.; Billingham M.E.; Fitzgerald P.; Yock P.G.; Robbins R.C.; Morris R.E.

On the horizon: clinical trials of new immunosuppressive strategies for autoimmune diseases
pp. 4027-4028(2)
Authors: Daikh D.I.; Wofsy D.

Evaluation of immunosuppressive induction regimens in renal transplantation
pp. 4029-4030(2)
Author: Opelz G.

Immunoglobulin-cytokine fusion molecules: the new generation of immunomodulating agents
pp. 4031-4036(6)
Authors: Kim Y.S.; Maslinski W.; Zheng X.X.; Schachter A.D.; Strom T.B.

Effects of cyclosporine a monotherapy on the incidence of rejection and infection episodes in heart transplant patients
pp. 4037-4043(7)
Authors: Seydoux C.; Stumpe F.; Hurni M.; Ruchat P.; Fischer A.; Mueller X.; von Segesser L.; Goy J.J.

Intestinal metabolism of cyclosporine a in human heart transplant recipients
pp. 4044-4044(1)
Authors: Lehle K.; Kirchner G.; Sewing K.F.; Rupprecht L.; Merk J.; Preuner J.G.

Evaluation of the AxSYM CyA assay compared with HPLC, TDx monoclonal and EMIT with both pretreatments
pp. 4045-4047(3)
Author: Steimer W.

A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: sandimmune and neoral
pp. 4048-4053(6)
Authors: Shah M.B.; Martin J.E.; Schroeder T.J.; First M.R.

A novel effect of cyclosporine a on lymphocyte migration to allograft and recipient lymphoid tissue
pp. 4054-4056(3)
Authors: Maksymowicz M.; Ziolkowska A.; Janczewska S.; Cybulska E.; Olszewski W.L.

Plasma and low-density lipoprotein lipid peroxidation in cyclosporine a-treated children after liver transplant
pp. 4057-4059(3)
Authors: Granot E.; Shemesh P.; Rivkin L.; Kohen R.

Specific immunosuppression of the indirect recognition pathway
pp. 4060-4061(2)
Authors: Suciu-Foca N.; Cortesini R.

Enhanced efficacy of repeated anti-NCD8 monoclonal antibody therapy by high-dose cyclosporine treatment
pp. 4062-4063(2)
Authors: Allan J.S.; Slisz J.K.; Vesga L.; Arn J.S.; Yamada K.; Sachs D.H.; Madsen J.C.

New trails in transplantation: how to exploit the potential of sirolimus in clinical transplantation
pp. 4064-4065(2)
Authors: Groth C.G.; Brattstrom C.; Claesson K.; Backman L.

Comparative efficacy of liposomal FK506 with FK506
pp. 4066-4067(2)
Authors: Moffatt S.D.; McAlister V.; Calne R.Y.; Metcalfe S.

Therapeutic drug monitoring of tacrolimus in kidney transplantation: 9-month follow-up
pp. 4068-4069(2)
Authors: Brunet M.; Torregrosa J.V.; Oppenheimer F.; Corbella J.

Tacrolimus use in kidney-pancreas recipients is associated with less acute renal dysfunction than cyclosporine
pp. 4070-4072(3)
Authors: Fleck P.R.; Schroeder T.J.; Dauod A.J.; Peddi V.R.; First M.R.

Tacrolimus (FK506) monotherapy provides potent and significant suppression of allogeneic foetal rat pancreatic allograft rejection1
pp. 4073-4074(2)
Authors: du Toit D.F.; Muller C.; Mouton Y.; Page B.; Mattysen J.; Lyners R.; Woodroof C.

Mycophenolate mofetil in ongoing chronic kidney allograft dysfunction
pp. 4075-4076(2)
Authors: Senn B.; Rochat P.; Schwarzkopf A.K.; Weinreich T.; Binswanger U.

Mycophenolate mofetil immunosuppression in high-risk renal transplant recipients
pp. 4077-4078(2)
Authors: Abouna G.M.; Al Arrayed A.S.; Farid E.; Awad C.K.; Sharqawi S.A.-D.; Tantawi M.

A comparison of the safety and efficacy of mycophenolate mofetil, prednisone and cyclosporine and mycophenolate mofetil, and prednisone and tacrolimus
pp. 4079-4081(3)
Authors: Daoud A.J.; Schroeder T.J.; Shah M.; Hariharan S.; Peddi V.R.; Weiskittel P.; First M.R.

Pharmacoeconomic analysis of mycophenolate mofetil versus azathioprine in primary cadaveric renal transplantation
pp. 4082-4084(3)
Authors: Baker G.M.; Martin J.E.; Jang R.; Schroeder T.J.; Armitstead J.A.; Myre S.; First M.R.

Comparison between mycophenolate mofetil and azathioprine based immunosuppression in pediatric renal transplantation from living related donors
pp. 4085-4086(2)
Authors: Antoniadis A.; Papachristou F.; Gakis D.; Takoudas D.; Sotiriou I.

Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient
pp. 4087-4089(3)
Authors: Basara N.; Blau W.I.; Kiehl M.G.; Romer E.; Rudolphi M.; Bischoff M.; Kirsten D.; Sanchez H.; Gunzelmann S.; Fauser A.A.

Pharmacokinetics of mycophenolic acid in the early period after kidney transplantation
pp. 4090-4091(2)
Authors: Wollenberg K.; Krumme B.; Pisarski P.; Schollmeyer P.; Kirste G.

Immunosuppression with cyclosporin A in combination with mycophelolate mofetil suppresses rejection of allogeneic fetal rat pancreatic allografts
pp. 4092-4093(2)
Authors: du Toit D.F.; Muller C.; Page B.; Mattysen J.; Lyners R.

How to handle mycophenolate mofetil in combination with tacrolimus?
pp. 4094-4095(2)
Authors: Braun F.; Canelo R.; Schutz E.; Shipkora M.; Lorf T.; Hanack U.; Niedmann D.; Armstrong V.W.; Oellerich M.; Ringe B.

Postmarketing evaluation of mycophenolate mofetil-based triple therapy immunosuppression compared with a conventional azathioprine-based regimen reveals enhanced efficacy and early pharmacoeconomic benefit after renal transplantation
pp. 4096-4097(2)
Authors: Wuthrich R.P.; Weinreich T.; Schwarzkopf A.K.; Candinas D.; Binswanger U.

A prospective randomised study of CSA monotherapy versus CSA plus mycophenolate mofetil in cadaveric renal transplant recipients
pp. 4098-4098(1)
Authors: Sells R.A.; Bakran A.; Brown M.W.; Grinyo J.; Hammad A.; Hyatt D.; Owens G.

Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimus
pp. 4099-4103(5)
Authors: Schorlemmer H.U.; Bartlett R.R.; Lindner J.K.; Kurrle R.

Preventive efficacy of 15-deoxyspergualin against progression of apoptotic cell death in acute rejection after rat liver transplantation
pp. 4104-4105(2)
Authors: Yamamoto H.; Ohdan H.; Shintaku S.; Miyata Y.; Marubayashi S.; Asahara T.; Ito H.; Dohi K.

Functional characterization of HP12: a novel immunosuppressant purified from helleborus species
pp. 4106-4107(2)
Authors: Linke S.; Dufter C.; Kerek F.; Jung M.; Watzlik A.; Jung T.; Opelz G.; Terness P.

In vitro transcription and translation of the tumour suppressor protein P53: qualitative and quantitative effects of FK506 and rapamycin
pp. 4108-4109(2)
Authors: Metcalfe S.M.; Cockman M.; Milner A.J.

Effective oral ganciclovir prophylaxis against cytomegalovirus disease in heart transplant recipients
pp. 4110-4112(3)
Authors: Mullen G.M.; Silver M.A.; Malinowska K.; Lawless C.E.; Lichtenberg R.C.; Barath P.C.; O'Keefe P.J.; Robinson J.A.; Yeldandi V.

Selective immunotherapy of iddm: a discussion based on new findings from the RIP-LCMV model for autoimmune diabetes
pp. 4115-4121(7)
Author: von Herrath M.G.

Protection of murine systemic lupus erythematosus by an I-E -chain transgene
pp. 4122-4123(2)
Authors: Izui S.; Ibnou-Zekri N.; Iwamoto M.; Kobayakawa T.

Strategies for the treatment of intraocular inflammatory disease
pp. 4124-4125(2)
Authors: Nussenblatt R.B.; Schiffman R.; Fortin E.; Robinson M.; Smith J.; Rizzo L.; Csaky K.; Gery I.; Waldmann T.; Whitcup S.M.

Anti-tnf therapy is useful in rheumatoid arthritis and crohn's disease: analysis of the mechanism of action predicts utility in other diseases
pp. 4126-4127(2)
Authors: Feldman M.; Taylor P.; Paleolog E.; Brennan F.M.; Maini R.N.

Bromocriptine markedly inhibits progression of murine retrovirus-induced immunodeficiency
pp. 4128-4129(2)
Authors: Rosso di San Secondo V.E.M.; Fitch C.; Aniasi A.; Close F.T.; Sirchia G.; Freeman M.E.

FK-506 (tacrolimus) therapy for an unusual SLE-like disease
pp. 4130-4131(2)
Authors: Kilian K.; Banyai A.; Karadi A.; Miklos K.; Patranyi G.G.; Paloczi K.

Prevention of experimental autoimmune diabetes in mice by treatment with leflunomide
pp. 4132-4133(2)
Authors: Stosic-Grujicic S.; Dimitrijevic M.; Bartlett R.R.

Cyclosporine in the treatment of autoimmune disorders: a 10-year experience
pp. 4134-4134(1)
Authors: Mitrovic D.; Popovic M.; Glisic B.; Pavlica L.; Dimitrijevic M.

Comparative study of the clinical efficacy of four dmards (leflunomide, methotrexate, cyclosporine, and levamisole) in patients with rheumatoid arthritis
pp. 4135-4136(2)
Authors: Popovic M.; Stefanovic D.; Pejnovic N.; Popovic R.; Glisic B.; Obradovic S.; Dimitrijevic M.

Immunomodulatory activity of malononitrilamides, derivatives of leflunomide's primary metabolite, on models of experimental rheumatoid arthritis
pp. 4137-4139(3)
Authors: Schorlemmer H.U.; Bartlett R.R.; Schleyerbach R.

Prevention of islet graft destruction in diabetic mice and rats by temporary Anti-IL-2 receptor therapy: comparison of different strategies
pp. 4140-4142(3)
Authors: Kuttler B.; Mathieu C.; Bulfone-Paus S.; Bouillon R.; Diamantstein T.; Hahn H.-J.

Leflunomide effectively treats naturally occurring immune-mediated and inflammatory diseases of dogs that are unresponsive to conventional therapy
pp. 4143-4148(6)
Authors: Gregory C.R.; Stewart A.; Sturges B.; DeManvelle T.; Cannon A.; Ortega T.; Harb M.; Morris R.E.

Effects of leflunomide on experimental autoimmune myocarditis with special reference to the dendritic cells
pp. 4149-4150(2)
Authors: Dimitrijevic M.; Milenkovic M.; Milosavljevic P.; Colic M.

Successful treatment of autoimmune hemolytic anemia with intravenous immunoglobulin in a patient with AIDS
pp. 4151-4152(2)
Author: Gonzalez C.A.

Modulation of immunoglobulin dysregulation in graft versus host-and systemic lupus erythematosus-like diseases by malononitrilamides
pp. 4153-4155(3)
Authors: Schorlemmer H.U.; Bartlett R.R.

Cyclosporine in the treatment of steroid-dependent and steroid-resistant idiopathic nephrotic syndrome in children
pp. 4156-4157(2)
Authors: Garcia C.; Michelon T.; Barros V.; Mota D.; Uhlmann A.; Randon R.; Ramalho H.; Abbud Filho M.

Monitoring serum beta-2 microglobulin is useful for detecting patients with increased risk of acute rejection during reduction in immunosuppression
pp. 4158-4159(2)
Authors: Saraiva Camara N.O.; Nishida S.; Silva M.S.; Pestana J.O.M.; Pereira A.B.; Sesso R.; Pacheco-Silva A.

Prolongation of concordant xenograft survival by treatment with FTY720
pp. 4163-4165(3)
Authors: Miyata Y.; Ohdan H.; Noriyuki T.; Shintaku S.; Shibata S.; Yamamoto H.; Fan X.H.; Fudaba Y.; Yoshioka S.; Asahara T.; Fukuda Y.; Dohi K.

Xenogeneic rejection mechanisms shown by intravital microscopy
pp. 4166-4167(2)
Authors: Hammer C.; Linke R.; Seehofer D.; Diefenbeck M.

Allogeneic and xenogeneic vascular injury and protection
pp. 4168-4169(2)
Authors: Pober J.S.; Schechner J.S.; Murray A.G.; Sultan P.; Kirkiles N.; Tereb D.; Wilson J.; McNiff J.M.; Askenase P.W.; Tellides G.; Lorber M.I.

Combination therapy of malononitrilamides and tacrolimus (FK 506) induced long-term xenograft survival
pp. 4170-4173(4)
Authors: Schorlemmer H.U.; Kurrle R.

Variable in vitro inhibition of HLA-specific alloantibody-mediated cytotoxicity by intravenous human immunoglobulin
pp. 4177-4179(3)
Authors: Urra J.M.; de la Torre M.; Alcazar R.; Peces R.; Ferreras I.; Garca-Chico P.

Prolongation of rat fetal pancreas allograft survival using a nondepleting anti-CD4 monoclonal antibody W3/25
pp. 4180-4183(4)
Authors: Muller C.J.F.; Du Toit D.F.; Beyers A.D.; Page B.J.; Muller N.

Heme oxygenase inhibits nitric oxide synthase by degrading heme: a negative feedback regulation mechanism for nitric oxide production
pp. 4184-4185(2)
Authors: Turcanu V.; Dhouib M.; Poindron P.

Modulation of cytokine production following intranasal administration of antigenic peptide
pp. 4186-4187(2)
Authors: Burkhart C.; Liu G.; Metzler B.; Wraith D.C.

Diltiazem modulates monokine production by isolated human monocytes
pp. 4188-4190(3)
Authors: D'Ambrosio A.; Giacomini E.; Quaranta M.G.; Quintieri F.

Phytoalexin resveratrol (3-4'-5-trihydroxystilbene) modulates granulocyte and monocyte endothelial adhesion
pp. 4191-4193(3)
Authors: Ferrero M.E.; Bertelli A.A.E.; Pellegatta F.; Fulgenzi A.; Corsi M.M.; Bertelli A.

Positive effects of tacrolimus in a case of CIDP
pp. 4194-4194(1)
Authors: Ahlmen J.; Andersen O.; Hallgren G.; Peilot B.

Influence of clinical immunosuppression on proinflammatory cytokines and acute-phase proteins
pp. 4195-4195(1)
Authors: Semenkov V.F.; Artemjeva O.V.; Shishina R.N.; Golubeva V.L.; Serova L.D.

Immunosuppressant effect on fas antigen expression and p53 of an experimental tumor
pp. 4196-4196(1)
Authors: Yokoyama I.; Hayakawa A.; Hayashi S.; Kobayashi T.; Negita T.; Namii Y.; Nagasaka T.; Koike C.; Tachi Y.; Takagi H.

Inhibition of PDGF-stimulated rat smooth muscle cell proliferation by MNA 279 and MNA 715
pp. 4197-4199(3)
Authors: Czech J.; Schwab W.; Schorlemmer H.U.

Effect of WF10 (TCDO) on antigen presentation - III
pp. 4200-4204(5)
Authors: McGrath M.S.; Benike C.; Kuehne F.-W.; Engleman E.

Long-term cardiac allograft survival in mice treated with malononitrilamide 715
pp. 4205-4206(2)
Authors: Gerauer K.; Maier S.; Emmanuilidis K.; Chambron N.; Zantl N.; Pfeffer K.; Heidecke C.-D.

Editorial(s)
pp. 4209-4209(1)

Prologue
pp. 4210-4213(4)
Author: Land W.

The nature of ischemia/reperfusion injury
pp. 4217-4223(7)
Authors: Massberg S.; Messmer K.

Oxygen free radicals in experimental organ transplantation - Approaches to Graft Rejection
pp. 4227-4227(1)
Author: Land W.

Free radical generation in human endothelial cells exposed to anoxia and reoxygenation
pp. 4228-4232(5)
Author: Zweier J.L.

Comment to the previous paper of J. Zweier: demonstration of reactive oxygen species in reperfused human kidney transplants - Approaches to Graft Rejection
pp. 4233-4234(2)
Authors: Illner W.D.; Land W.

Postischemic Reperfusion Injury and Cytokines
pp. 4237-4238(2)
Author: Land W.

Regulation of endothelial cell function by pro- and anti-inflammatory cytokines
pp. 4239-4243(5)
Authors: Mantovani A.; Garlanda C.; Introna M.; Vecchi A.

Cytokines 1: upregulation of cytokine gene expression and cytokine release in postischemic reperfused organs and transplants
pp. 4244-4245(2)
Authors: Stangl M.; Land W.

Postischemic Reperfusion Injury and Adhesion Molecules in Nontransplant Models
pp. 4249-4250(2)
Author: Land W.

Endothelial cell adhesion molecules in inflammation and postischemic reperfusion injury
pp. 4251-4256(6)
Authors: Beekhuizen H.; van de Gevel J.S.

Analysis of intragraft adhesion molecules and their release in clinical liver transplantation: impact of reperfusion injury
pp. 4257-4259(3)
Authors: Viebahn R.; Thoma M.; Kinder O.; Schenk M.; Lauchart W.; Becker H.D.

Ischemia/Reperfusion Injury and Upregulation of Major Histocompatibility Complex Expression
pp. 4263-4263(1)
Author: Land W.

Upregulation of major histocompatibility complex-expression under ischemic conditions in experimental models
pp. 4264-4266(3)
Author: Shackleton C.R.

Possible Role of Postischemic Reperfusion Injury as Initiator of Allorecognition/Alloactivation
pp. 4269-4269(1)
Author: Land W.

Integrins and T helper cell activation
pp. 4270-4274(5)
Authors: van Seventer G.A.; Semnani R.T.; Palmer E.M.; McRae B.L.; van Seventer J.M.

Contribution of Postischemic Reperfusion Injury to Development of Allograft Arteriosclerosis: Many Questions in Regard to Pathogenic Pathways
pp. 4277-4277(1)
Author: Land W.

Postischemic reperfusion injury and allograft arteriosclerosis - Organ Protection in the 1990's
pp. 4278-4280(3)
Authors: Fellstrom B.; Akuyrek L.M.; Backman U.; Larsson E.; Melin J.; Zezina L.

Ischemia reperfusion injury and chronic allograft rejection
pp. 4281-4284(4)
Authors: Szabo A.; Heemann U.

''pro'' and ''con'' debate: should we change current policies in organ procurement/organ transplantation with the goal to reduce cold ischemia times?
pp. 4287-4287(1)
Author: Land W.

Decreasing the cold ischemia time
pp. 4288-4290(3)
Author: Abendroth D.

What is a reasonably short cold ischemia time in kidney transplantation?
pp. 4291-4293(3)
Author: Offermann G.

Cadaver kidney graft outcome in relation to ischemia time and HLA match
pp. 4294-4296(3)
Author: Opelz for the Collaborative Transplant Study G.

Organ procurement policy: should we reduce cold ischemia times?
pp. 4297-4302(6)
Authors: Lange H.; Kuhlmann U.

Epilogue
pp. 4303-4303(1)
Author: Land W.

Notes on the bellagio task force report on transplantation, bodily integrity, and the international traffic of organs
pp. 4307-4308(2)
Author: Santiago-Delpin E.

Expected costs for small-scale organ transplantation programs - Selected Notes for Future Policy
pp. 4309-4313(5)
Authors: Stavem K.; Kristensen K.O.F.

Early catheter removal decreases incidence of urinary tract infections in renal transplant recipients
pp. 4314-4316(3)
Authors: Rabkin D.G.; Stifelman M.D.; Birkhoff J.; Richardson K.A.; Cohen D.; Nowygrod R.; Benvenisty A.I.; Hardy M.A.

A trial of oral magnesium supplementation in renal transplant recipients receiving cyclosporine 1
pp. 4317-4319(3)
Authors: Nguyen T.; Steiner R.W.

Renal transplantation: potential source of microfilarial transmission
pp. 4320-4321(2)
Authors: Gupta R.K.; Jain M.

Increased dosage requirement and rejection after neoral conversion in pediatric liver transplant patients
pp. 4322-4324(3)
Authors: Cao S.; Cox K.L.; Berquist W.; So S.; Concepcion W.; Monge H.; Esquivel C.O.

Liver disease in tropical renal transplant patients: an autopsy study
pp. 4325-4326(2)
Authors: Ramakrishna B.; Pillai G.; John G.T.; Date A.

Massive ingestion of tacrolimus in a young liver transplant patient
pp. 4327-4329(3)
Authors: Odoul F.; Talbotec C.; Boussa N.; Le Guellec C.; Furet Y.; Maurage C.; Breteau M.

Quality of life after liver transplantation - Strategies for Surgical Investigations
pp. 4330-4333(4)
Authors: Seiler C.A.; Muller M.; Fisch H.U.; Renner E.L.

Analysis of pig-map after small bowel transplantation in pigs
pp. 4334-4336(3)
Authors: Escartn A.; Bueno J.; Lampreave F.; Gonzalez-Ramon N.; Pineiro A.; Cruz I.; Garca-Gil F.A.

Effect of low-molecular-weight heparin on development of cardiac allograft vascular disease following heart transplantation in rats
pp. 4337-4339(3)
Author: Hisatomi K.

A reliable method for long-term (24-hour) hypothermic transport of cardiac graft
pp. 4340-4343(4)
Authors: Ferrera R.; Hadour G.

Mycophenolate mofetil and FK506: two novel immunosuppressants in murine corneal transplantation
pp. 4344-4347(4)
Authors: Reis A.; Reinhard T.; Sundmacher R.; Braunstein S.; Godehardt E.

Impaired hepatic mitochondrial function reserve in brain-dead pigs
pp. 4351-4355(5)
Authors: Sato T.; Asanuma Y.; Yasui O.; Kurokawa T.; Shibata S.; Koyama K.

Arterial ketone body ratio in clinical liver transplantation
pp. 4356-4359(4)
Authors: Kitabayashi K.; Gores G.J.; Krom R.A.F.